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AbsTrACT
background cOPD is a heterogeneous disease, 
but there is little consensus on specific definitions for 
cOPD subtypes. Unsupervised clustering offers the 
promise of ’unbiased’ data-driven assessment of cOPD 
heterogeneity. Multiple groups have identified cOPD 
subtypes using cluster analysis, but there has been no 
systematic assessment of the reproducibility of these 
subtypes.
Objective We performed clustering analyses across 10 
cohorts in north america and europe in order to assess 
the reproducibility of (1) correlation patterns of key 
cOPD-related clinical characteristics and (2) clustering 
results.
Methods We studied 17 146 individuals with 
cOPD using identical methods and common cOPD-
related characteristics across cohorts (FeV1, FeV1/FVc, 
FVc, body mass index, Modified Medical research 
council score, asthma and cardiovascular comorbid 
disease). correlation patterns between these clinical 
characteristics were assessed by principal components 
analysis (Pca). cluster analysis was performed using 
k-medoids and hierarchical clustering, and concordance 
of clustering solutions was quantified with normalised 
mutual information (nMi), a metric that ranges from 0 to 
1 with higher values indicating greater concordance.
results the reproducibility of cOPD clustering 
subtypes across studies was modest (median nMi range 
0.17–0.43). For methods that excluded individuals 
that did not clearly belong to any cluster, agreement 
was better but still suboptimal (median nMi range 
0.32–0.60). continuous representations of cOPD clinical 
characteristics derived from Pca were much more 
consistent across studies.
Conclusions identical clustering analyses across 
multiple cOPD cohorts showed modest reproducibility. 
cOPD heterogeneity is better characterised by 
continuous disease traits coexisting in varying degrees 
within the same individual, rather than by mutually 
exclusive cOPD subtypes.
InTrOduCTIOn
COPD is characterised by significant disease hetero-
geneity,1 2 but there is little consensus regarding 
specific definitions for distinct COPD subtypes 
or phenotypes, terms which have been used inter-
changeably in the literature. Unsupervised clus-
tering is intuitively appealing because it offers a 
data-driven, objective assessment of COPD hetero-
geneity, and several groups have used cluster anal-
ysis to identify COPD subtypes.3–9 However, a 
recent systematic review showed substantial differ-
ences in clustering results across studies,10 calling 
the reproducibility of these subtypes into question. 
Since clinical translation of COPD subtypes depends 
on reproducibility, this is a critical question for the 
clinical application of clustering-defined subtypes.
On the other hand, the conclusions that may be 
drawn from the previously mentioned systematic 
review are limited, since the wide variety of methods 
used in the different studies precluded quantitative 
meta-analysis and subject-level assessment of cluster 
reproducibility. By comparing average COPD-related 
characteristics across clusters, the authors identified 
two COPD subtypes that seemed to be reasonably 
replicable across studies. These subtypes were charac-
terised by (1) severe airflow limitation, low body mass 
index (BMI) and poor health status and (2) moderate 
airflow limitation, high BMI and cardiovascular 
comorbidities.
Key messages
What is the key question?
 ► Are COPD subtypes identified through 
clustering algorithms reproducible in 
independent patient populations?
What is the bottom line?
 ► COPD subtypes identified through clustering 
algorithms have modest reproducibility 
in the contexts studied, but continuous 
representations of COPD clinical characteristics 
are more reproducible.
Why read on?
 ► This is the largest, multicohort study explicitly 
designed to assess the reproducibility of COPD 
subtypes, and it provides novel insights about 
the nature of clinical variability in COPD.
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To directly assess the reproducibility of COPD clustering 
subtypes, we performed uniform clustering analyses in 10 inde-
pendent large cohorts of patients with COPD to which authors 
had access to individual patient data. These analysis results 
were shared across cohorts in order to (1) assess the similarity 
of correlation patterns between selected COPD clinical charac-
teristics and (2) determine the reproducibility of unsupervised 
clustering across cohorts. These experiments demonstrate that 
for many important COPD-related clinical characteristics such 
as FEV1, emphysema and health-related quality of life, subjects 
with COPD are distributed along a continuous spectrum rather 
than being clustered into clearly distinct subgroups. As a result, 
clustering results are only modestly reproducible across indepen-
dent studies, and continuous representations of COPD clinical 
variability are more consistent.
MeThOds
subjects
The participating study populations were Clinical Identification 
of Phenotypes in COPD (CLIPCOPD),7 COPDGene,11 Evalu-
ation of COPD Longitudinally to Identify Predictive Surrogate 
Endpoints (ECLIPSE),12 International collaborative effort on 
chronic obstructive lung disease: exacerbation risk index cohorts 
(ICE COLD ERIC),13 LifeLines,14 Lovelace,15 Leuven,16 Lung 
Health Study,17 the National Jewish Health (NJH) cohort and 
The Phenotype and Course of Chronic Obstructive Pulmonary 
Disease (PAC-COPD).18 Subjects included in this analysis were 
self-described Caucasian subjects meeting spirometric criteria 
for COPD (defined as postbronchodilator FEV1 and FVC ratio 
<0.7 with the exception of one cohort14 using prebronchodi-
lator values). Institutional review board approval was obtained 
from the relevant participating academic centres for all study 
populations. Further details are provided in the online supple-
mentary data.
Clustering features
Features used as inputs for the clustering analysis were selected 
based on availability within all 10 studies, excluding age and pack-
years, which may be drivers of disease itself rather than manifes-
tations. Accordingly, the clustering features finally selected were: 
FEV1 per cent of predicted, FVC per cent of predicted, FEV1/
FVC ratio, BMI, Modified Medical Research Council (MMRC) 
dyspnoea score (0–4) and self-reported asthma and cardiovas-
cular disease diagnosis. Additional details on clustering features 
are included in the online supplementary data.
statistical and clustering analyses
All analyses were performed in R (V.3.1.0). To assess the simi-
larity of the correlation patterns between variables, we first 
performed principal component analysis (PCA) in each cohort, 
and then we compared the feature loadings for each principal 
component (PC) across datasets.
To determine reproducibility of clustering solutions, we iden-
tified clusters in each cohort using hierarchical and k-medoids 
clustering according to the methods outlined by Horvath19 
using a predetermined range of parameter settings, then we 
transferred these clustering solutions across cohorts by using 
supervised random forests predictive models (figure 1). The 
predictive accuracy of these models was quantified by out-of-bag 
cross-validation.
We generated 23 clustering solutions per cohort in order 
to explore a wide range of possible solutions for the methods 
under study, for a total of 230 solutions. A distinct feature of the 
hierarchical clustering algorithm is that it identifies ‘poorly clus-
tered’ subjects that are not sufficiently similar to other members 
in their assigned cluster.20 In subsequent analyses, the hierar-
chical clustering results were analysed with and without these 
‘poorly clustered’ individuals.
We quantified the extent to which each ‘source’ clustering 
solution matched the clusters generated in the other cohorts 
using normalised mutual information (NMI), a measure of 
subject-level agreement.21 For each cohort, the best NMI 
solutions were considered the most reproducible cluster solu-
tions, and the COPD-related characteristics of these clusters 
were described by means of descriptive statistics. We deter-
mined, based on the average characteristics of each cluster 
solution, whether any of the clusters resembled the previously 
mentioned frequently reported COPD subtypes (ie, the ‘severe 
airflow limitation, low BMI and poor health status’, and the 
‘moderate airflow limitation, high BMI and cardiovascular 
comorbidities’).
A more comprehensive set of features was explored in two 
study cohorts, COPDGene and ECLIPSE (COPDGene-ECLIPSE 
substudy). These features included all of the features in the 
main study, as well as airway wall thickness (Pi10), quantita-
tive emphysema (LAA950), number of self-reported respiratory 
exacerbations over the previous 12 months, chronic bronchitis 
symptoms and the Saint George’s Respiratory Questionnaire 
(SGRQ) total score. Additional details are included in the online 
supplementary data.
resulTs
Clinical characteristics of the study samples
The clinical characteristics of the analysed subjects from all 10 
cohorts are shown in table 1.
The number of subjects in each cohort ranged from 60 to 
5198. Some studies included patients with COPD with a wide 
range of airflow limitation, whereas others had a predominance 
of severely affected or less severely affected subjects. Studies 
drew from populations in the USA and Northern and Southern 
Europe.
Correlation patterns and clustering importance of COPd 
clinical features
PCA demonstrated that the correlation pattern between variables 
was extremely similar across cohorts (figure 2), despite the fact 
that the distribution of variables differed across them (table 1). 
The majority of the variance was captured by the first three PCs 
in all participating cohorts (see online supplementary figure 1). 
In addition, when the data were visualised with multidimen-
sional scaling, it resembled a continuous surface that tracked 
closely with spirometric disease severity in all study popula-
tions (see online supplementary figure 2). Thus, the correlation 
pattern and general structure of the data was highly consistent 
across cohorts, but the data were not clustered in distinct groups.
As explained in the Methods section, prior to clustering, 
features were automatically weighted by the clustering proce-
dure. The importance of each feature for determining cluster 
membership was very similar between datasets (figure 3). FEV1 
per cent of predicted contributed most to the clustering solutions 
across all participating study populations, followed by FEV1/FVC 
and FVC. MMRC and BMI contributed to cluster solutions in 
some study populations but not others, and self-reported asthma 
and cardiovascular comorbidity did not contribute meaningfully 
to any clustering solutions.
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Figure 1 Overview of cluster generation, transfer and concordance assessment. For each cohort, 23 ‘source’ clustering solutions (S1 to S23) are 
generated (total of 230 solutions across the 10 cohorts). Each solution is transferred to the other cohorts via a predictive model (T1 to T23). Each 
solution is also labelled according to its parent cohort, thus source solution 1 from cohort 1=S1C1. Each cohort ultimately produces 230 cluster 
solutions (23 source solutions and 207 transferred solutions, which are ‘predicted into’ each cohort). The green, red and dark blue colours correspond 
to cluster results generated by a specific cluster method and set of parameters (eg, ‘k-medoids with k=2’). NMI, normalised mutual information.
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reproducibility of clustering results across cohorts
Figure 4 shows that, within each of the cohorts, the reproduc-
ibility of the k-medoid and hierarchical clustering results was 
modest (range of median NMI across 10 cohorts is 0.17–0.43 
and maximum NMI is 0.29–0.72). However, when poorly classi-
fiable subjects (identified by the hierarchical clustering method) 
were excluded, agreement across cohorts was higher (range of 
median NMI 0.32–0.60 and maximum NMI 0.61–1.0). The 
most highly reproducible cluster solutions varied greatly in terms 
of the number of identified clusters and cluster characteristics 
between cohorts. The clinical characteristics of these clusters are 
shown in online supplementary tables 2–11. The median accu-
racy of the supervised prediction models used to transfer cluster 
solutions between cohorts was 90.3% (IQR 82.3%–96.3%). We 
also examined whether these ‘best NMI’ solutions resembled 
the two clusters identified in the review by Pinto et al. Due to 
small cluster size, the NJH cohort solutions were not consid-
ered. Six of the nine best NMI solutions identified a cluster 
with severe airflow limitation and moderate MMRC dyspnoea 
scores (table 2), and three study populations identified a cluster 
characterised by increased BMI and cardiovascular comorbid-
ities with mild-to-moderate airflow limitation (table 3). While 
these clusters appeared similar in their average characteristics, 
the average concordance of subject assignment to these clusters 
across different cohorts ranged from 50% to 86%.
COPdGene-eClIPse substudy with a more extensive set of 
COPd-related features
We considered the possibility that the modest reproducibility 
may be due to the limited set of variables common to all 10 
cohorts. To observe the reproducibility of clustering on a more 
comprehensive set of variables, we applied the same clustering 
methods to a larger set of COPD-related clinical measures in 
subjects in spirometric Global Initiative for Chronic Obstruc-
tive Lung Disease (GOLD) stages 2–4 in the COPDGene and 
ECLIPSE studies. In addition to the seven features used in the 
main study, this analysis included measures of airway wall thick-
ness (Pi10), quantitative emphysema from chest CT (LAA950), 
prior 12-month exacerbation history, chronic bronchitis and 
SGRQ score. The variable importance measures demonstrate 
that spirometric measures contribute the most to these cluster 
solutions, with the next most important measures being LAA950, 
MMRC and SGRQ score (figure 3). These analyses confirmed 
the findings from the main study, demonstrating modest repro-
ducibility for the clusters that included all subjects and higher 
reproducibility for clustering approaches that allowed a propor-
tion of subjects to be unclassified. PCA plots of these data also 
confirm that these data are distributed along a continuum rather 
than in discrete clusters (figure 5).
We also considered the possibility that our observed modest 
cluster reproducibility may be due to differences in the under-
lying data distributions between cohorts. To address this question, 
we performed a clustering analysis in the COPDGene-ECLIPSE 
substudy limited to subjects in GOLD spirometric stage 2 only. 
The reproducibility of these clustering solutions is comparable 
to our other experiments (see online supplementary figure 3).
Because some of the solutions allowing for unclassified 
subjects did demonstrate high reproducibility, we examined 
the characteristics of these clusters in both COPDGene and 
ECLIPSE. The COPDGene analysis identified three clusters that 
corresponded to a healthier group (higher FEV1 % predicted, 
less emphysema and less airway wall thickening), an emphy-
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(see online supplementary table 12). However, the proportion 
of unclustered subjects was high (86% of all subjects). The 
most reproducible clustering solution in ECLIPSE identified 
six clusters, and also demonstrated a high rate of unclassified 
subjects (52%).
dIsCussIOn
This study is the first investigation of the reproducibility of 
COPD clustering results across multiple independent cohorts, 
and it demonstrates that (1) COPD subtypes identified through 
clustering show only modest reproducibility and (2) the variable 
manifestations of COPD are better represented by continuous 
traits, such as airflow limitation or quantitative emphysema, 
which can coexist to varying degrees within the same individual, 
rather than categorisations of patients in mutually exclusive 
COPD subtypes/phenotypes. These findings have a number of 
implications for the future study of COPD subtypes. First, the 
concept of continuous representations of COPD, similar to the 
concept of ‘treatable traits’,22 is a useful alternative to clusters 
that highlights distinct aspects of COPD, while allowing for the 
fact that these treatable traits may be present to varying degrees 
in different subjects. Second, for some sets of variables, standard 
data-driven clustering methods may not demonstrate levels of 
reproducibility appropriate for clinical use.
Interpretation of results
The clustering data used in this study capture many important 
aspects of COPD pathology and have been used in previous 
attempts to classify COPD.3 6 7 22 23 The modest reproducibility 
of clustering solutions can be explained by the fact that these 
data do not have strong clustering structure and are better 
characterised by a continuum of disease severity. However, this 
observation applies only to the limited set of COPD clinical char-
acteristics used in this study. It is possible that other COPD-re-
lated characteristics may lead to more reproducible clusters.
Despite modest clustering reproducibility, certain clusters 
tend to recur across multiple studies. Clustering often identifies 
a ‘severe COPD’ cluster with low FEV1, low BMI and dyspnoea. 
Figure 2 Loadings of input features (cluster variables) for the first four principal components (PC) in all cohorts. BMI. body mass index; CVD, 
cardiovascular disease; MMRC, Modified Medical Research Council.
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The COPDGene-ECLIPSE substudy confirms that this cluster 
also has extensive CT emphysema. The other commonly occur-
ring cluster is an ‘airway-predominant cluster’ characterised by 
moderately impaired FEV1 and elevated BMI. In the COPD-
Gene-ECLIPSE substudy, this group also had thickened airway 
walls and relatively little CT emphysema. These two clusters 
resemble the clusters identified by Pinto et al, providing addi-
tional support to the concept of ‘emphysema-predominant’ and 
‘airway-predominant’ COPD.
While our results demonstrate limitations of clustering, they 
do not indicate that phenotypic differences between subjects 
with COPD are small or negligible. On the contrary, our data 
confirm that COPD encompasses a wide range of clinical presen-
tations, because the average characteristics of clusters were quite 
different. It is also important to note that (1) reproducibility can 
vary by subtype and (2) many subtype definitions are reproduc-
ible in the sense that predictive models can be used to identify 
groups of subjects in other datasets with similar characteristics. 
Thus, our findings demonstrate that clustering, as a means to 
define subtypes in an unbiased manner, is only modestly repro-
ducible for a set of variables that includes many of the most 
commonly used phenotypic measures of COPD.
Implications of findings
This study has a number of important implications for the future 
study of COPD subtypes. First, it demonstrates that reproduc-
ibility of clustering results cannot be assumed across independent 
cohorts. Second, it demonstrates that continuous representa-
tions of COPD clinical variability are an alternative approach 
to characterising COPD heterogeneity that are better suited to 
the continuous nature of many key COPD-related phenotypic 
measures. These continuous representations are similar to the 
concept of ‘treatable traits’ that has been previously proposed as 
Figure 3 Heat map of relative feature importance for clustering by cohort. Colours represent importance values generated by unsupervised random 
forests clustering. Higher values indicate that a given feature had a larger impact on the clustering results than other features in that dataset. Results 
for primary analysis in all 10 cohorts are shown in panel A. Results for the COPDGene and ECLIPSE substudy with more clustering features are shown 
in panel B.
Figure 4 Reproducibility of different clustering methods across 
10 cohorts. Distribution of normalised mutual information (NMI*) is 
shown for clustering with partitioning around medoids (PAM, in blue), 
hierarchical clustering including unclassified subjects (HC+U, in green) 
and hierarchical clustering excluding unclassified subjects (HC, in red).
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a strategy to improve the management and prognosis of patient 
with COPD.22 Unlike clusters, treatable traits are not mutually 
exclusive since any given patient can manifest more than one 
‘phenotypic’ trait. For instance, for two patients with the same 
amount of airflow limitation and emphysema, one may have 
bronchiectasis and the other may not, and both of them may or 
may not have pulmonary hypertension. Third, it may be useful 
to use differences in clinically relevant outcomes such as risk of 
exacerbation, mortality or FEV1 decline to define group bound-
aries and COPD subtypes. This entails a shift in the general 
conception of COPD subtypes, because it implies that there may 
be multiple distinct sets of subtypes that depend on the specific 
clinical outcome of interest. However, the concept of treat-
ment-specific or outcome-specific subtypes is already well-estab-
lished in clinical practice (ie, roflumilast for subjects with COPD 
and chronic bronchitis to reduce exacerbations). Fourth, the 
definition of COPD subtypes may benefit from the identifica-
tion of novel features, including genomic or proteomic features, 
which more effectively identify distinct COPD subtypes. Fifth, 
clustering methods that identify a ‘core’ of clustered individuals 
are more reproducible than methods that assume that all subjects 
can be classified. Finally, clustering can be useful for data explo-
ration, as long as its potential limitations regarding reproduc-
ibility are recognised.
strengths and limitations
This study has a number of strengths. As noted by Pinto et al, 
previous efforts to address cluster reproducibility in COPD have 
been limited by extensive heterogeneity in methods between 
studies.10 Our collaborative effort addressed this issue by 
performing identical clustering analyses across multiple cohorts, 
resulting in insights that would have been difficult to obtain from 
studying these cohorts individually. We used multiple clustering 
methods and explored a wide range of clustering parameters. To 
our knowledge, this is the largest and most comprehensive replica-
tion effort for cluster-based complex disease subtype identification.
This study also has important limitations. Because the vari-
ables used in the primary analysis were limited to those available 
in all participating study populations, this set of features does not 
fully capture the phenotypic spectrum of COPD. However, the 
clustering data used in this study capture many important aspects 
of COPD pathology and have been used in previous attempts to 
classify COPD.3 6 7 23 24 In addition, when a more comprehen-
sive set of variables was assessed in the COPDGene-ECLIPSE 
substudy, the level of reproducibility was still modest. Second, 
while all studies included subjects with FEV1/FVC <0.7, there 
were still differences in the distribution of variables, enrolment 
criteria and subject selection between studies. This variability 
may have limited the concordance of clustering solutions across 
studies. However, to address this concern, we performed clus-
tering for an even more well-defined group of only GOLD 2 
subjects in COPDGene and ECLIPSE, and the results of this anal-
ysis were consistent with the overall study results, suggesting that 
Table 2 Clinical characteristics of patients included in the clusters resembling the ‘severe airflow limitation, low BMI and poor health status’ 
subtype
Cohort ClIPCOPd COPdGene eClIPse ICeCOlderIC leuVen PAC-COPd
n (% of the cohort) 144 (39%) 880 (20%) 250 (12%) 51 (13%) 95 (17%) 58 (17%)
FEV1 (%predicted) 41.8 (11.6) 26.8 (7.4) 24.8 (4.7) 27.9 (6.7) 29.6 (6.4) 32 (8.0)
FEV1/FVC (%) 47.7 (11.2) 34.9 (7.6) 30.3 (4.2) 38.2 (10.3) 37.5 (7.4) 41.1 (8.0)
FVC (%predicted) 71.4 (15.8) 58.8 (12.3) 63.7 (11.9) 63.0 (14.9) 63.2 (9.9) 57.9 (9.3)
BMI (kg/m2) 25.4 (4.3) 26.2 (5.7) 23.9 (4.1) 23.5 (3.2) 23.7 (5.3) 24.9 (3.5)
MMRC (0–4) 2.3 (1.0) 3.2 (0.7) 2.5 (0.8) 2.5 (1.3) 2.4 (1.1) 1.9 (1.3)
Asthma, % 1 27 26 2 0 79
CVD, % 36 23 20 14 37 7
Values are mean (SD) unless otherwise noted. Complete description of best NMI cluster solutions for each cohort are available in online supplementary tables 2–11.
BMI. body mass index; CVD, cardiovascular disease; MMRC, Modified Medical Research Council; NMI, normalised mutual information.
Table 3 Clinical characteristics of patients included in the 
clusters resembling the ‘moderate airflow limitation, high BMI and 
cardiovascular comorbidities’ subtype
Cohort ICeCOlderIC leuVen PAC-COPd
n (% of the cohort) 90 (22.3%) 60 (10.9%) 45 (13.2%)
FEV1 (%predicted) 71.2 (6.3) 50.6 (7.2) 63.8 (4.1)
FEV1/FVC (%) 63.3 (3.6) 58.2 (6.7) 65.8 (4.3)
FVC (%predicted) 91.9 (10.6) 68.7 (7.8) 71.7 (4.7)
BMI (kg/m2) 29.1 (6.0) 30.1 (5.6) 31.5 (3.5)
MMRC (0–4) 1.3 (1.3) 2.1 (0.9) 1.4 (0.8)
Asthma, % 1 0 64
CVD, % 21 45 31
Values are mean (SD) unless otherwise noted. Complete description of best NMI 
cluster solutions for each cohort are available in online supplementary tables 2–11.
BMI. body mass index; CVD, cardiovascular disease; MMRC, Modified Medical 
Research Council; NMI, normalised mutual information.
Figure 5 Principal components analysis plot of clustering variables 
used in COPDGene clustering. Visualisation of data by the first three 
principal components (PC) in the COPDGene clustering analysis with 
spirometric, chest CT imaging and clinical data.
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incomplete sampling was not likely to be a major driver of these 
results. Third, certain variables related to medical history, such 
as asthma or cardiovascular disease, are ascertained primarily by 
self-report and may not be uniform across studies. This would 
limit the ability to identify potential clusters related specifically 
to those variables. Fourth, our analysis of clustering methods was 
not exhaustive. It was outside the scope of this effort to exhaus-
tively survey the performance of all available clustering methods. 
Fifth, for those methods that allowed for ‘unclustered’ subjects, 
the unclustered rate was quite high for the best NMI solutions 
in some cohorts. This likely reflects the poor separability of the 
underlying data rather than a shortcoming of the specific clus-
tering method, since this method has been applied successfully 
in other scenarios.20 Finally, non-smoking subjects with COPD 
are under-represented in these cohorts, and characterisation of 
heterogeneity in non-smoking COPD requires further study.25
Conclusions
This study of the replicability of clustering-defined COPD 
subtypes across multiple international cohorts found that 
COPD heterogeneity is best represented by continuous traits 
(such as airflow limitation or quantitative emphysema) coex-
isting in varying degrees within the same individual, rather 
than by mutually exclusive COPD subtypes/phenotypes. This 
is an important perspective to inform future efforts to charac-
terise COPD heterogeneity.
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